literature

HIV mutation literature information.

"Mutations M184V and Y115F in HIV-1 reverse transcriptase discriminate against ""nucleotide-competing reverse transcriptase inhibitors""."

PMID: 18728003 2008 The Journal of biological chemistry

Abstract: M184V and Y115F, or increased.

Abstract: RT enzymes containing the isolated mutations M184V and Y115F cause 2-3-fold increases in IC(50) values, while the combination of the two mutations causes a >15-fold increase.

Abstract: Binding studies revealed that the M184V change reduces the affinity to INDOPY-1, while Y115F facilitates binding of the natural nucleotide substrate and the combined effects enhance the ability of the enzyme to discriminate against the inhibitor.

Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.

PMID: 17403997 2007 Antimicrobial agents and chemotherapy

Abstract: For non-ATP-dependent discrimination toward DOT-TP, high levels of resistance were found for RT bearing the Q151M mutation with family mutations, while RT bearing only the M184V or the Y115F mutation conferred no resistance to DOT-TP.

Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.

PMID: 17417971 2007 Retrovirology

Result: The mutations most commonly observed (sometimes transiently) after the detection of K65R included K20R (3 animals), M41L (3 animals), S68G/K/N (12 animals), K70H/N/T/Q (9 animals), W88S (6 animals), Y115F (9 animals), F116W (6 animals), V118I (3 animals), I178M (6 animals), L214F (11 animals), and K219Q/R/E/N/D/H/G (7 animals) (table 1).

Table: Y115F

Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.

PMID: 17457088 2007 AIDS (London, England)

Abstract: Reverse transcriptase resistance mutations emerging on therapy differed between the groups: zidovudinelamivudine (M41L, D67N, K70R, M184V, L210W, T215Y); zidovudineabacavir (M41L, D67N, K70R, L210W, T215F/Y, K219Q); lamivudineabacavir (K65R, L74V, Y115F, M184V).

HIV-1 subtype B protease and reverse transcriptase amino acid covariation.

PMID: 17500586 2007 PLoS computational biology

Result: A62V, K65R, and Y115F are mutations that cluster with Q151M but may also occur with Type II (but not Type I) TAMs.

Result: The mutations included in this analysis were the 23 positively associated mutations in Table 2 and 11 additional clinically relevant NRTI-resistance mutations (K65R, A62V, T69ins, L74I/V, V75M, Y115F, M184V, and K219R/E/N).

Figure: Includes the 23 mutations obtained from the mutation pairs with highest positive association (Table 2) in bold, and 11 additional clinically relevant nucleo

In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.

PMID: 16436719 2006 Antimicrobial agents and chemotherapy

Abstract: SPD754 susceptibility was reduced 1.2- to 2.2-fold against isolates resistant to zidovudine (M41L, T215Y/F, plus a median of three additional nucleoside analogue mutations [NAMs]) and/or lamivudine (M184V) and was reduced 1.3- to 2.8-fold against isolates resistant to abacavir (L74V, Y115F, and M184V plus one other NAM) or stavudine (V75T/M, M41L, T215F/Y, and four other NAMs).

In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.

PMID: 16982781 2006 Antimicrobial agents and chemotherapy

Abstract: Abacavir resistance was characterized by the accumulation of the M184V, Y115F, and K65R mutations in the abacavir culture, while the M184V and L74V mutations were selected in combination with lamivudine.

Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action.

PMID: 17020946 2006 Journal of virology

Abstract: While INDOPY-1 susceptibility is unaffected by mutations associated with NNRTI or multidrug NRTI resistance, mutations M184V and Y115F are associated with decreased susceptibility, and mutation K65R confers hypersusceptibility to INDOPY-1.

Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.

PMID: 17057610 2006 Journal of acquired immune deficiency syndromes (1999)

Abstract: Six viral failures occurred, including 2 with K65R mutations (alone or associated with Y115F and M184V).

Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.

PMID: 15616314 2005 Antimicrobial agents and chemotherapy

Abstract: Human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) derivatives with D113E, Y115F, F116Y, Q151E/N, and M184V mutations were studied for their phosphorolysis-mediated resistance to the nucleoside RT inhibitors (NRTIs) zidovudine and stavudine and for their inhibition by the nonnucleoside analogs (NNRTIs) efavirenz and nevirapine.

Browser Board

Co-occurred Entities

Filtrator